TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07710196: A 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome

Sponsor: Nacuity Pharmaceuticals, Inc. · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 80 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$15,086,080

Rescue Site Savings

+$9,947,384

Unlock Full NCT07710196 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07710196 Rescue Dossier →